AirHelp Launches First Unlimited, Free Flight-Tracking App for Passengers
Offers real-time flight tracking, disruption alerts, and built-in options for extra protection
Passengers are automatically notified when they are eligible for compensation
Travelers can easily protect and insure their future trips
Turns complex air passenger rights into clear, actionable steps
WASHINGTON, May 28, 2025 /CNW/ -- AirHelp, the leading travel tech company supporting passengers with flight disruptions, today announces the launch of its new AirHelp Flight and Claim Tracker. As the first unlimited, free flight-tracking app on the market, the platform serves as an essential travel companion for passengers navigating an increasingly disrupted travel landscape this summer and beyond.
Unlimited Flight Tracking & Real-Time Compensation Alerts
Flight disruptions are on the rise, as more than 236 million passengers across the U.S. were affected by delays and cancelations in 2024. AirHelp's new app is designed to put passengers back in control, transforming their travel experience from one of uncertainty to confidence. With unlimited real-time flight tracking, instant compensation alerts, and built-in options for extra protection and insurance, the app keeps passengers informed, protected, and a step ahead of disruptions.
Navigating air passenger rights can be overwhelming, and most passengers are unaware of when they are eligible for compensation or how to claim it. AirHelp's app changes that, turning any smartphone into a personal passenger rights assistant. It alerts users the moment they qualify for compensation and guides them through the process. With a free eligibility check for flights from the past three years, the app ensures passengers can easily claim what they are rightfully owed.
Features for Effortless Travel
The AirHelp Flight and Claim Tracker is packed with several smart features to make travel easier and more connected for passengers. It includes live updates on gate changes, flight delays or cancellations and baggage belt numbers. The app syncs seamlessly with calendars and Gmail to import both past and upcoming flights, making it easier to stay organized.
Travelers can enjoy added peace of mind with extra protection, comfort, and dedicated assistance throughout their journey. Passengers can simply add AirHelp+ protection via the app to cover flight delays, cancellations, or baggage issues, ensuring they are not only supported during disruptions but are compensated quickly without hassle. AirHelp+ administers these insurance payouts within hours, which is on top of the compensation passengers can also claim for.
Speaking on the new app, Tomasz Pawliszyn, CEO at AirHelp said: "Flight disruptions are an increasing concern for passengers, especially as we approach the summer season. Our mission has always been to advocate for passengers, and with this new app, we are taking that commitment to the next level. Passengers now have access to an all-in-one tool that keeps them informed in real-time, helps them navigate flight disruptions or lost luggage, and ensures they can easily claim for compensation they are rightfully owed. As the industry continues to face uncertainty, our app is available to support passengers and streamline their travel experience."
Find out more about the AirHelp Flight and Claim Tracker and download it here.
Petition to save passenger rights
The EU is trying to cut passenger rights so drastically that 85% of delay claims would no longer qualify for compensation. It will mean longer delays, less compensation, and ZERO accountability.
Read more and sign the petition.
About AirHelp
AirHelp is a travel tech company tackling flight disruptions. Since 2013, it has won compensation for over 2.7 million passengers with a flight delay or cancellation. 10 million passengers have protected their flights with AirHelp+ Protection, and countless millions more benefit from the expert information freely available on airhelp.com. AirHelp has also just released its new app, which offers real-time flight tracking, disruption alerts, and options for extra protection, download it here!
AirHelp is dedicated to investing in a greener future - it has pledged to plant 1 tree for every 100 flight disruptions and so far, it has planted 108,324 trees. As air passenger rights advocates, AirHelp cares about people, and caring about people also means caring about the planet.
#1 source for flight compensation worldwide
With innovative artificial intelligence and a dedicated team of over 400 AirHelpers, AirHelp makes it easy for any traveler in the EU, UK and beyond to receive up to €600 for flight delays and cancellations. For more information about AirHelp, visit: https://www.airhelp.com/en-gb/.
For further information, please contact:
Tomasz Pawliszyn
CEO
AirHelp Inc.
[email protected]
SOURCE AirHelp
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
29 minutes ago
- Cision Canada
ImmunoGenesis to present IMGS-001 Phase 1a/1b Clinical Study Updates at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
IMGS-001 is first dual-specific PD-L1/PD-L2 antibody with cytotoxic killing function and is designed to treat the many "immune-excluded" cancers that are resistant to existing immunotherapies HOUSTON, May 30, 2025 /CNW/ -- ImmunoGenesis, a clinical-stage biotech company developing innovative, science-driven immunotherapies, announced today that a Trial in Progress poster for its first-in-human, Phase 1a/1b clinical trial of IMGS-001 will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago, Illinois from May 30 to June 3, 2025. This Phase 1a/1b first-in-human, open-label, multicenter study (NCT06014502) includes a dose escalation and an expansion portion to evaluate the safety, pharmacokinetics, and preliminary anti-tumor activity of IMGS-001 in adult patients with locally advanced or metastatic solid tumors refractory to standard-of-care treatment. The study will enroll approximately 25 patients in Phase 1a and up to 250 in Phase 1b. The first three of five planned dose cohorts have completed without any dose limiting toxicities (DLTs), with cohort 4 (10 mg/kg) now enrolling. "This clinical trial is an important first step to understand how IMGS-001 may potentially remove immunosuppressive cells while improving PD-1 pathway blockade to treat otherwise immunoresistant tumors that represent a significant unmet medical need," stated Charles Schweizer, PhD, Senior Vice President of Clinical Development at ImmunoGenesis. "We are pleased to discuss the study plan and progress at this important conference as we look ahead to sharing results." "We are encouraged by the early performance of IMGS-001 as we proceed with Phase 1 dose escalation in patients with a variety of advanced solid tumors," said James Barlow, President and CEO of ImmunoGenesis. "Initial low doses administered to date have been well-tolerated with no dose-limiting toxicities, and we are seeing promising early signs of anti-tumor activity in patients who have failed prior treatments. IMGS-001 has the potential to be a foundational therapy for immune-excluded tumors, addressing a major unmet need." ASCO Poster Presentation Title: A Phase 1a/1b study to evaluate the safety, tolerability, Pharmakokinetics, and anti-tumor activity of IMGS-001 in Patients with relapsed or refractory advanced solid tumors. Abstract: TS2686 | Poster Bd #: 324a Track: Developmental Therapeutics—Immunotherapy Location: Hall A -Posters and Exhibits | On Demand Time: June 2, 2025, 1:30 PM – 4:30 PM CDT About ImmunoGenesis ImmunoGenesis is a clinical-stage biotech company dedicated to transforming immuno-oncology by targeting key mechanisms of immune resistance. The company's lead product, IMGS-001, is a cytotoxic, dual-specific PD-L1/PD-L2 antibody currently in a Phase 1a/b clinical trial for the treatment of immune-excluded ("cold") tumors, which account for more than half of all cancers. In addition to its lead program, the company is developing a number of novel approaches to overcome immune resistance in cold tumors. ImmunoGenesis designs therapies to address the pathology of these tumors, overcoming immune exclusion to elicit a robust immune response. For more information, visit About IMGS-001, a PD-L1/PD-L2 Dual-Specific Inhibitor IMGS-001, the lead program at ImmunoGenesis, is a PD-L1/PD-L2 dual-specific monoclonal antibody with engineered cytotoxic effector function. IMGS-001 is the first molecule in clinical testing to target PD-L2 in addition to PD-L1, potentially improving blockade of the PD-1 pathway. The engineered effector function may enable IMGS-001 to eliminate immunosuppressive PD-L1- and/or PD-L2-expressing cells present in the tumor microenvironment, providing the potential to overcome immune resistance in immune-excluded tumors. Preclinical data showed that IMGS-001 drove higher response rates in head-to-head studies compared to currently available immunotherapies. IMGS-001 may provide a new foundational therapy with its innovative multitasking mechanism of superior blockade and cytotoxic effector function. IMGS-001 is being developed with support from the Cancer Prevention and Research Institute of Texas (CPRIT) DP200094 as well as an investment from the Cancer Focus Fund, LP. Contact ImmunoGenesis Investors: James Barlow President and CEO [email protected] SOURCE Immunogenesis Inc.
Cision Canada
an hour ago
- Cision Canada
BMO Recognized for Digital Innovation and Customer Experience Français
TORONTO, May 30, 2025 /CNW/ - BMO today announced it has received multiple recognitions for its leadership in delivering innovative digital solutions and experiences to help customers make real financial progress. Digital CX Awards from The Digital Banker: Outstanding Digital CX for Mobile Banking – Canada: Available in BMO's Mobile Banking app and Online Banking, the Enhanced Transaction Details feature provides customers with detailed information about credit and debit card transactions including merchant information and location. This provides customers a more comprehensive understanding of their transactions and spending habits. Excellence in Omni-Channel Customer Experience: BMO developed an approach to helping customers make progress towards the financial goals by delivering personalized and relevant multi-channel advice and guidance to support their journey. Customers are able to share their financial goals in-branch, over email, or on BMO Savings Goals, a feature available on the BMO Mobile Banking app and Online Banking. Editor's Choice Award from Banking Tech Awards: BMO was also recognized for its success in creating and integrating seamless digital experiences to meet customers where they are in their financial journey across four initiatives: InnoV8 Customer Feedback Assist: The large language model (LLM) powered tool is designed to help BMO address feedback received from customer reviews. Taking elements of a traditional dashboard and adding LLM powered data, this cohesive solution improves employees' workflow and helps support the continuous improvement efforts for customers. BMO SmartProgress: BMO SmartProgress is a free, online financial education platform accessible to all Canadians to help them learn about personal finance topics and make real financial progress. With over 40 interactive, customized modules on financial planning topics, including budgeting and credit management, homeownership and investing, Canadians can conveniently build their financial literacy anywhere and at any time. Digital Card Controls: A quick solution for customers facing time sensitive issues, BMO's Digital Card Controls feature suite helps customers when dealing with a lost wallet, damaged cards, or forgotten PINs. With this convenient solution, customers are empowered to manage their cards anywhere and at any time. BMO's Bank of the West Integration: Following BMO's 2021 acquisition of Bank of the West, BMO successfully integrated its systems in 2023, maintaining existing login credentials, converting digital profiles and guiding customers through an individualized onboarding journey. BMO's innovative approach included converting all money movement transactions, providing customized guidance and enhancing foundational technology for scale. The project successfully converted 1.8 million customers and over 500 branches. "At BMO, our commitment to elevating our customers' everyday banking experiences drives our digital and innovation agenda," said Mat Mehrotra, Chief Digital Officer and Head of Canadian Products, BMO. "These recognitions reinforce how we are empowering our customers by meeting them where they are with differentiated experiences that help them make real financial progress." The Digital CX Awards is the world's only program dedicated to recognizing pioneering innovation in the Digital Customer Experience across the Financial Services ecosystem. The awards honour excellence in the use of digital assets within the financial services industry and celebrates contributions to innovations, technological enhancements and commitments to digital transformation. The Editor's Choice Award is chosen by the editorial team of FinTech Futures, a globally trusted resource recognizing banking and fintech innovation. The award recognizes a financial services organization that has successfully delivered innovative and impactful technology projects, with tangible results and perceptible, positive impact. BMO continues to pave the way as a digitally enabled, future-ready bank, focused on delivering leading digital experiences that help customers make real financial progress. These recognitions demonstrate BMO's Digital First journey and build on the bank's strong track record of industry credits. For more information about the Digital CX Awards, please visit: BMO Financial Group is the seventh largest bank in North America by assets, with total assets of $1.4 trillion as of April 30, 2025. Serving customers for 200 years and counting, BMO is a diverse team of highly engaged employees providing a broad range of personal and commercial banking, wealth management, global markets and investment banking products and services to 13 million customers across Canada, the United States, and in select markets globally. Driven by a single purpose, to Boldly Grow the Good in business and life, BMO is committed to driving positive change in the world, and making progress for a thriving economy, sustainable future, and inclusive society.
Cision Canada
an hour ago
- Cision Canada
BIOVAXYS ANNOUNCES CONSOLIDATION AND CONCURRENT BROKERED PRIVATE PLACEMENT OFFERING FOR GROSS PROCEEDS OF UP TO $3,000,000
VANCOUVER, BC, May 30, 2025 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (" BioVaxys" or the " Company") announces a proposed consolidation of the common shares of the Company (the " Common Shares") on the basis of ten (10) pre-consolidation Common Shares for one (1) post-consolidation Common Share (the " Consolidation"), and a concurrent brokered private placement offering (the " Offering") consisting of a minimum of 5,714,285 units of the Company (each, a " Unit") at a post-Consolidation price of $0.35 per Unit for minimum gross proceeds of $2,000,000 and a maximum of 8,571,428 Units at a post-Consolidation price of $0.35 per Unit for maximum gross proceeds of up to $3,000,000. Consolidation The Company currently has 293,425,203 Common Shares issued and outstanding, and it is anticipated that immediately following the Consolidation, excluding Common Shares to be issued in connection with this Offering, the Company will have approximately 29,342,520 Common Shares issued and outstanding, prior to rounding of fractional Common Shares. The exercise or conversion price of the Company's convertible securities and the number of Common Shares issuable thereunder will also be proportionately adjusted upon completion of the Consolidation. No fractional Common Shares will be issued as a result of the proposed Consolidation. Any fractional Common Shares resulting from the proposed Consolidation will be rounded up in the case of a fractional interest that is one-half (1/2) of a Common Share or greater, or rounded down in the case of a fractional interest that is less than one-half (1/2) of a Common Share, to the nearest whole number of Common Shares, and no cash consideration will be paid in respect of fractional Common Shares rounded down to the nearest whole Common Share. The Company will issue a subsequent news release in respect of the proposed Consolidation to announce the effective date of the Consolidation, the new CUSIP and ISIN for the post-Consolidation Common Shares, and any other relevant details, and file all necessary documentation with the Canadian Securities Exchange (the " CSE") in respect of the proposed Consolidation. The post-Consolidation Common Shares will continue to trade on the CSE under the Company's existing name and trading symbol. The Consolidation remains subject to requisite approvals, including acceptance by the CSE. Offering The Company has entered into an agreement with D12 Capital Markets Inc. (" D12") and its affiliate, Foundation Markets Inc. to act as agents (the " Agents") in connection with the Offering. Completion of the Offering will be contingent upon the Company issuing a minimum of 5,714,285 Units at a post-Consolidation price of $0.35 per Unit for minimum gross proceeds of $2,000,000. Each Unit will consist of one (1) post-Consolidation common share in the capital of the Company (each, a " Post-Consolidation Common Share") and one (1) Post-Consolidation Common Share purchase warrant (each, a " Post-Consolidation Warrant"). Each Post-Consolidation Warrant will entitle the holder thereof to purchase one Post-Consolidation Common Share at a post-Consolidation price of $0.60 for a period of 36 months from the closing date of the Offering. The Company intends to use the net proceeds raised from the Offering for research and development, general corporate purposes and working capital. Upon successful closing of the Offering, the Agents will receive a cash commission equal to 8% of the gross proceeds committed to the Company from any party introduced by the Agents. Such payment shall be paid by the Company in equal share to the Agents as per their direction. Closing of the Offering is anticipated to occur on or about June 30, 2025, or such other date as the Company and the Agents may agree upon provided such date is on or before July 14, 2025. Closing of the Offering and payment of the Agents' commission are subject to the satisfaction of certain conditions, including, but not limited to, acceptance by the CSE. Subject to compliance with applicable regulatory requirements and in accordance with National Instrument 45-106 – Prospectus Exemptions (" NI 45-106"), the Units issuable under the Offering will be offered for sale to purchasers in all provinces and territories of Canada, except Quebec, pursuant to the listed issuer financing exemption under Part 5A of NI 45-106. The securities to be issued pursuant to the sale of the Units under the Offering will not be subject to resale restrictions in accordance with applicable Canadian securities laws. There is an offering document dated May 30, 2025, related to the Offering that can be accessed under the Company's profile at and on the Company's website at Prospective investors should read this offering document before making an investment decision. This news release does not constitute an offer to sell or a solicitation of an offer to buy of any securities in the United States, or in any jurisdiction in which such offer, solicitation or sale would be unlawful. The securities described herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the " U.S. Securities Act"), or any state securities laws, and may not be offered or sold within the United States except in compliance with the registration requirements of the U.S. Securities Act and applicable state securities laws or pursuant to available exemptions therefrom. About BioVaxys Technology Corp. BioVaxys Technology Corp. ( a biopharmaceuticals company registered in British Columbia, Canada, is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX™ immune-educating technology platform and it's HapTenix© tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization for food allergy, and other immunological diseases. Through a differentiated mechanism of action, the DPX™ platform delivers instruction to the immune system to generate a specific, robust, and persistent immune response. The Company's clinical stage pipeline includes maveropepimut-S (MVP-S), based on the DPX™ platform, and in Phase IIB clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant Ovarian Cancer. MVP-S delivers antigenic peptides from survivin, a well-recognized cancer antigen commonly overexpressed in advanced cancers, and also delivers an innate immune activator and a universal CD4 T cell helper peptide. MVP-S has been well tolerated and has demonstrated defined clinical benefit in multiple cancer indications as well as the activation of a targeted and sustained, survivin-specific anti-tumor immune response. BioVaxys is also developing DPX™+SurMAGE, a dual-targeted immunotherapy combining antigenic peptides for both the survivin and MAGE-A9 cancer proteins to elicit immune responses to these two distinct cancer antigens simultaneously, DPX™-RSV for Respiratory Syncytial Virus, DPX+rPA for peanut allergy prophylaxis, and BVX-0918, a personalized immunotherapeutic vaccine using its proprietary HapTenix© 'neoantigen' tumor cell construct platform for refractive late-stage ovarian cancer. BioVaxys common shares are listed on the CSE under the stock symbol "BIOV" and trade on the Frankfurt Bourse (FRA: 5LB) and in the U.S. on the OTC Markets (OTCQB marketplace). For more information, visit and connect with us on X and LinkedIn. ON BEHALF OF THE BOARD Signed " James Passin" James Passin, Chief Executive Officer Phone: +1 740 358 0555 Cautionary Statements on Forward Looking Information This news release includes certain "forward-looking information" and "forward-looking statements" (collectively " forward-looking statements") within the meaning of applicable securities legislation. All statements, other than statements of historical fact, included herein, without limitation, statements relating to the future operating or financial performance of the Company, are forward-looking statements. Forward-looking statements are frequently, but not always, identified by words such as "expects", "anticipates", "believes", "intends", "estimates", "potential", "possible", and similar expressions, or statements that events, conditions, or results "will", "may", "could", or "should" occur or be achieved. Forward-looking statements in this news release relate to, among other things, the proposed Consolidation, including the ratio thereof and timing thereof, and the Offering, including the size and use of proceeds, and the timing and ability of the Company to close the Offering, including obtaining approval of the Offering from the CSE. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those expressed or implied in such forward-looking statements. Forward-looking statements reflect the beliefs, opinions and projections on the date the statements are made and are based upon a number of assumptions and estimates, primarily the assumption that BioVaxys will be successful in developing and testing vaccines, that, while considered reasonable by BioVaxys, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies including, primarily but without limitation, the risk that BioVaxys' vaccines will not prove to be effective and/ or will not receive the required regulatory approvals. With regards to BioVaxys' business, there are a number of risks that could affect the development of its biotechnology products, including, without limitation, the need for additional capital to fund clinical trials, its lack of operating history, uncertainty about whether its products will complete the long, complex and expensive clinical trial and regulatory approval process for approval of new drugs necessary for marketing approval, uncertainty about whether its autologous cell vaccine immunotherapy can be developed to produce safe and effective products and, if so, whether its vaccine products will be commercially accepted and profitable, the expenses, delays and uncertainties and complications typically encountered by development stage biopharmaceutical businesses, financial and development obligations under license arrangements in order to protect its rights to its products and technologies, obtaining and protecting new intellectual property rights and avoiding infringement to third parties and their dependence on manufacturing by third parties. Many factors, both known and unknown, could cause actual results, performance or achievements to be materially different from the results, performance or achievements that are or may be expressed or implied by such forward-looking statements and the parties have made assumptions and estimates based on or related to many of these factors. Such factors include, without limitation, the ability of the Company to complete the Consolidation and the Offering on the terms proposed or at all, and the ability to obtain necessary approvals, including the approval of the CSE. BioVaxys does not assume any obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by applicable securities laws.
